Neuroectodermal Tumors, Primitive
A group of malignant tumors of the nervous system that feature primitive cells with elements of neuronal and/or glial differentiation. Use of this term is limited by some authors to central nervous system tumors and others include neoplasms of similar origin which arise extracranially (i.e., NEUROECTODERMAL TUMORS, PRIMITIVE, PERIPHERAL). This term is also occasionally used as a synonym for MEDULLOBLASTOMA. In general, these tumors arise in the first decade of life and tend to be highly malignant. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2059)
Subtype terms (2)
More specific conditions that are subtypes of Neuroectodermal Tumors, Primitive in the MeSH hierarchy.
- Medulloblastoma
162 drugs (94 approved, 68 experimental)
- Neuroectodermal Tumors, Primitive, Peripheral
12 drugs (8 approved, 4 experimental)
Drugs by status
Phase 2 trials (16)
Phase 1 trials (35)
- thalidomide
- acetylcysteine
- azurin-derived cell-penetrating peptide p28
- doxorubicin
- g207
- gemcitabine
- tacrolimus
- trametinib
- aldesleukin
- hydrocortisone
- Filgrastim
- ribociclib
- vincristine
- ifosfamide
- celecoxib
- mycophenolate
- sonidegib
- cyclophosphamide
- temozolomide
- allogeneic lymphocytes
- topotecan
- Anti-thymocyte Globulin (Rabbit)
- veliparib
- zoledronic acid
- her-2 car-t cells
- dcr-myc
- mesna
- fludarabine
- cytarabine
- tamoxifen
- +5 more
Other trials (1)
Organizations
Organization Involved with Phase 3 Indications (6)
Organization Involved with Phase 2 Indications (44)
- Daiichi Sankyo
- Amgen
- Imclone
- Merck
- DNAtrix, Inc.
- Jubilant DraxImage Inc.
- NantCell, Inc.
- PharmaMar
- National Institutes of Health (NIH)
- National Institute of Neurological Disorders and Stroke (NINDS)
- Burzynski Research Institute
- Centre Leon Berard
- Children's Cancer and Leukaemia Group
- University of London
- Cornell University
- Harvard University
- University of Washington
- Herbert Irving Comprehensive Cancer Center
- McGill University
- Newcastle University
- Oregon Health and Science University
- Pediatric Brain Tumor Consortium
- Stanford University
- Thomas Jefferson University
- University of Florida
- University of Leeds
- University of Louisville
- University of Milan
- University of Southern California
- University of Tennessee
- +14 more
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (8)